Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03096418 · ClinicalTrials.gov registry record · Phase 4
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
A Phase 4 study of Breast Neoplasm Female, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT03096418: Recruiting Phase 4 study of Breast Neoplasm Female, sponsored by University of Wisconsin, Madison.
NCT03096418 is a Phase 4 study of Breast Neoplasm Female that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 50 participants, below the 174-participant average among 8 other Breast Neoplasm Female trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03096418, a Phase 4 study of Breast Neoplasm Female, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day cycle. Participants will continue with paclitaxel for cycles 2-4 prior to surgery.
Primary Outcome
To test if high cancers with high chromosomal instability (CIN) respond to paclitaxel better than low CIN cancers. Response determined by the percent decrease in linear measurement of tumor size on the greatest dimension per RECIST-like criteria
Conditions Studied
Interventions
- DRUG Paclitaxel
Study Locations (2)
Iowa
- University of Iowa Health Care/Holden Comprehensive Cancer Center - Iowa City
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-03-13 |
| Est. Completion | 2026-06 |
| Phase | Phase 4 |
What NCT03096418 shows while recruiting
NCT03096418 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 174-participant average among 8 other Breast Neoplasm Female trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Breast Neoplasm Female appearing as the primary indexed condition, and to 1 intervention - of which Paclitaxel is the first listed.
NCT03096418 reports a single indexed study location in Iowa, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03096418 about?
NCT03096418 is a clinical study titled "Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response". The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day ...
What is the current status of trial NCT03096418?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2017-03-13. Estimated completion is 2026-06.
What conditions does trial NCT03096418 study?
This clinical trial studies the following conditions: Breast Neoplasm Female.
What interventions are being tested in trial NCT03096418?
The interventions under investigation include: Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT03096418?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03096418 being conducted?
This trial has 2 study locations across Iowa, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasm Female
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03096418's enrollment target sits among peer trials
50 5th of 8 higher than 4 of 8 other Breast Neoplasm Female trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasm Female trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
RECRUITING · NA
-
The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
RECRUITING · NA
-
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
ACTIVE NOT RECRUITING · Phase 2
-
Study on Physical Activity's Relationship With Cancer and Cognition
COMPLETED · NA
-
Web-Base App To Improve Aromatase Inhibitor Adherence
COMPLETED · NA
-
Mayo Designed Soft Tissue Ultrasound-Detectable Marker
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI